Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies

TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies

US Patent 10882893 · Granted Jan 5, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Mutant variants of PD-1 receptor with selective binding to PD-L1 and uses thereo2025
Mutant variants of PD-1 receptor with selective binding to PD-L1 and uses thereo2025
BTNL9 and ERMAP as novel inhibitors of the immune system for immunotherapies2025
Compounds and methods for treatment of bacterial infections2025
Monoclonal antibodies against IgV domain of B7-H3 and uses thereof2025
Antibodies to human B7x for treatment of metastatic cancer2025
Antagonist antibodies against human immune checkpoint CEACAM1 (CD66a) and formul2024
Monoclonal antibodies against human tim-32024
Engineered PD-1 variants2024
Residue-based pharmacophore method for identifying cognate protein ligands2022
Precision activation of HIV-specific CTLS to eliminate reactivated latent T cell2022
Prevention and treatment of viral infections2022